LL-37: Wound-Healing Research, Antimicrobial Claims and Safety
LL-37 is a peptide associated with the human cathelicidin system. Research distinguishes the mature peptide from its precursor, hCAP18, and from other related protein regions. Those names should not be treated as interchangeable materials. Original cathelicidin research
For a reader asking whether LL-37 helps wounds or treats infection, the useful answer begins with the trial setting. A topical cream studied in a particular ulcer population needs its own evidence summary. Keep that separate from claims about systemic administration, general immune enhancement or other diseases.
The selected clinical studies below provide a mixed picture. This profile preserves favorable findings, negative findings and exploratory observations, with their different meanings visible.
What is being studied under the LL-37 name?
Early human cathelicidin research describes hCAP18/LL-37 as comprising a conserved prosequence and a C-terminal peptide called LL-37. Laboratory work on the precursor or other domains does not automatically describe an experiment with the same administered material as a clinical LL-37 preparation. Zaiou and colleagues, original indexed abstract
When checking a study, copy its full material description into your notes. Then record whether the investigation measured naturally occurring LL-37, added a preparation to a laboratory system, or administered a formulation to participants. Do not merge those categories into a single list of proven treatment effects.
Our recommendation is to keep a separate entry for the intervention and the measurement. A study measuring a molecule in wound fluid is not, simply by that fact, a study demonstrating the benefit of administering it. The study-reading guide can help organize the distinction.
The early venous-ulcer study
Grönberg and colleagues reported an early randomized, placebo-controlled study involving 34 people with difficult-to-heal venous leg ulcers. It included a four-week blinded topical treatment phase. The indexed abstract reports favorable healing findings in the two lower-concentration groups. 2014 original research record
Treat this as an early signal in its specific setting. For a detailed appraisal, examine allocation, baseline wound characteristics, the chosen outcome and the precision of the comparison. We accessed the original indexed abstract excerpt for this study, not a full review of its methods and safety tables.
Do not use the positive title of an early paper as a substitute for reading subsequent trials. A useful profile should show how later work tests the same general idea and where the findings become more complicated.
The larger HEAL LL-37 trial
The 2021 HEAL LL-37 trial randomized 148 patients with difficult-to-heal venous leg ulcers to topical LL-37 or placebo, alongside compression therapy. The full-population analysis did not identify a statistically significant improvement in healing. A post hoc analysis suggested benefit in participants with larger wounds, and the authors called for a further adequately powered study of that group. Original abstract
The overall finding belongs at the beginning of the summary. Place the subgroup finding after it, labeled as post hoc. Do not use the subgroup observation to rewrite the full-population result as established benefit.
For a reading exercise, create two lines in your notes: “Planned population result” and “Exploratory subgroup observation.” Fill them separately from the paper. That layout makes it harder for an interesting hypothesis to displace the original trial question. See our negative-study explainer for a fuller discussion.
The diabetic-foot-ulcer cream study
Miranda and colleagues reported a randomized, double-blind study of LL-37 cream in diabetic foot ulcers with mild infection. Over four weeks, the LL-37 group had a greater increase in granulation index at the reported weekly assessments. The abstract did not show corresponding significant reductions in IL-1α, TNF-α or aerobic bacterial colonization. 2023 original abstract
This study is useful because its outcomes should not all be compressed into one statement. Preserve the favorable wound-related measure alongside the inflammatory and microbiological results. Do not turn a granulation finding into a claim that the cream eradicated infection.
When comparing this paper with the venous-ulcer trials, retain the different ulcer population and formulation. The study question should remain visible rather than disappearing behind the shared peptide name. Our review used the original abstract; detailed eligibility, analysis and safety tables were not comprehensively appraised.
Three studies, three evidence entries
Use the following original reading map to keep the study questions distinct. Consult the individual sources above for the research findings.
| Evidence entry | What to preserve in your summary | Question for further appraisal |
|---|---|---|
| Early topical venous-ulcer research | Small early trial, formulation and reported healing outcome | How precise and reproducible was the comparison? |
| Later venous-ulcer trial | Overall result separately from the post hoc subgroup | Was the subgroup subsequently tested as a planned question? |
| Diabetic-foot-ulcer cream research | Wound measure separately from inflammation and colonization | Which outcomes improved, and which did not? |
Do not pool these rows informally into an overall “success rate.” Instead, ask whether a proposed conclusion names the same wound type, intervention, comparator and outcome as the source supporting it.
For example, a proposed sentence about complete wound closure should send you to the paper’s closure endpoint. A sentence about reducing bacterial burden should send you to the microbiological result. If the source does not supply that outcome, revise the sentence rather than filling the gap with a mechanism.
Why antimicrobial claims need direct evidence
When evaluating a claim about infection, ask which organism, model and outcome were studied. Keep laboratory activity, wound colonization and patient outcomes in separate entries. Request an original clinical source for any claim that a preparation treats a specific infection.
Do not assume that a positive wound-related result answers every infection question. Likewise, do not use a measurement of naturally occurring LL-37 to infer the benefit of a new administration method. These are different research questions that need their own evidence.
For an individual with a wound or suspected infection, use the profile as a source-reading aid when speaking with a qualified clinician. It should not replace diagnosis, wound assessment or established care, and it provides no instructions for substituting LL-37 for an antibiotic or other treatment.
Safety: what the current FDA resource says
FDA flags potential immunogenicity and characterization concerns for compounded LL-37 and insufficient information to determine human safety. It also notes nonclinical concerns involving male reproduction and tumor-promoting effects in some tissues. These are identified concerns, not a quantified prediction for every person. FDA safety resource, checked September 2026
Keep the distinction between nonclinical findings and observed human events in your notes. Avoid claiming a known human event rate where the source provides none. At the same time, do not erase the concern because a short topical study used favorable tolerability language.
For each safety statement, request the route, formulation, participants, follow-up and denominator. If you have only an abstract, make that limitation explicit. “Not described in the abstract” and “did not occur” should never occupy the same field in an evidence record.
Topical research is not a systemic protocol
The intervention is part of the study question. Preserve the topical formulation when summarizing wound-cream research. Before discussing a different route, ask for research on that route rather than transferring the conclusion automatically.
Our editorial recommendation is to avoid translating published concentrations into a self-administration plan. A concentration calculation does not select an appropriate treatment, establish tolerability or determine whether a preparation matches the study material.
This profile intentionally does not give an injection schedule, escalation plan or wound-treatment recipe. If a product page presents one beside these studies, ask which original trial supports that exact use and whether its safety evidence was reviewed.
How to check a supplier’s evidence claim
Begin with the document itself. Does it identify the material and lot? What test was performed, and what question did it answer? Separate a laboratory report about sample composition from a clinical paper about an intervention.
The purity and COA guide explains why a percentage should not stand in for every quality question. The peptide identity guide provides a framework for matching names and actual materials.
For LL-37, pay particular attention to whether the cited evidence concerns the same formulation and intended research context. Do not treat a list of references as proof that each claim on a page is supported. Match one claim to one relevant result, then record the limits.
What would make the evidence more useful?
When assessing new research, prioritize a clearly defined clinical question, planned outcomes and transparent reporting. For a proposed subgroup benefit, look for a study that names the subgroup in advance. For an infection claim, look for the relevant clinical and microbiological outcomes. For a different route, request route-specific evidence.
Also ask whether the report provides complete wound closure, time to healing, recurrence, patient experience or other outcomes relevant to its stated purpose. Do not assume that all are present. Make the missing information part of the appraisal.
This is a proposed reading agenda, not a claim that a particular future study will be positive. A well-designed negative result would still help clarify the question.
Frequently asked questions
Is LL-37 proven to heal every type of wound?
Do not make that claim from the selected studies. Keep the ulcer type, formulation and measured outcome attached to each result, including the negative overall finding and the exploratory subgroup observation.
Does the diabetic-foot-ulcer study prove an antibacterial treatment effect?
Read its microbiological result separately from the wound measure. The favorable finding highlighted above should not be relabeled as bacterial eradication or generalized infection treatment.
Does a natural role in the body establish the safety of a product?
Do not use that reasoning to bypass product-specific and clinical evidence. Ask what was administered, to whom, by which route and with what reported safety observations.
Sources and review scope
This is a selected-source profile, not a systematic review. We checked original indexed research records, the original abstracts of the 2021 and 2023 trials, and the FDA safety resource. Full methods and all supplemental analyses were not comprehensively appraised. No specific supplier product was tested.
- Zaiou et al., 2003: cathelicidin precursor and peptide research
- Grönberg et al., 2014: early venous-ulcer trial
- Mahlapuu et al., 2021: HEAL LL-37
- Miranda et al., 2023: diabetic-foot-ulcer cream trial
- FDA: bulk-substance safety concerns
Confidence labels describe the reported statements, not certification of a compound or product.